Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil. CRE: high dosing, how much? by author
|
|
- Darcy Shields
- 5 years ago
- Views:
Transcription
1 Therapy of MDR/XDR Gram-negative bacteria: dealing with the devil CRE: high dosing, how much? George L. Daikos, MD National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece
2 Disclosures I have received research funding or honoraria from: Pfizer, Achaogen, Rempex, MSD, Gilead, Astellas.
3 CRE: high dosing, how much? Carbapenems Aminoglycosides Polymixins Tigecycline
4 Log10 cfu per lung at 24h % Time > MIC for Carbapenems with different 10 effects Craig WA. Clin Infect Dis 1998, 26: 1-12 Andes D & Craig WA. IJAA 2002; 19: % Moderately severe infection in a non- immunopressed patient Bactericidal effect ( 2-log10 kill) 20% Bacteriostatic effect (< 2-log kill) 100% Severe infection In immunosupressed patients Maximal effect?
5 Probability of Clinical Response with Meropenem of Febrile Neutropenic Patients with Bacteremia as a Function of %T>MIC Ariano et al. Annals of Pharmacotherapy 2005; 39: 32-8
6 Improving Exposure to Carbapenems Increasing the dose while keeping the dosage interval the same Administering the drug more frequently while keeping the dose fixed Increasing the duration of IV infusion
7 PTA (40% ft>mic) for meropenem in critically ill patien Roberts et al. J Antimicrob Chemother 2009; 64:
8 Can we Attain the Carbapenem PK/PD Targets for CPE Infections?
9 No. of Isolates Distribution of Meropenem MICs for 372 Consecutive K. pneumoniae Blood Isolates MICs (μg/ml) VIM KPC, KPC+VIM NO CARBAPENEMASE
10 Distribution of Meropenem MICs of 661 KPC-Kp (Italian Study Group on Resistant Infections) Percentage MIC (μg/ml) Tumbarello M J Antimicrob Chemother 2015; 70:
11 Activity of imipenem against VIM 1 metallo β lactamase producing Klebsiella pneumoniae in the murine thigh infection model VIM-negative MIC=0.12mg/L VIM-positive MIC=4mg/L Daikos GL et al Clin Microbiol Infect 2007; 13: VIM-positive MIC=2mg/L VIM-positive MIC=32mg/L
12 Comparison of the efficacies of two different doses of doripenem against carbapenemase-producing K. pneumoniae isolates in immunocompromised and immunocompetent animals. Bulik C C, Nicolau D P Antimicrob. Agents Chemother. 2010;54: MIC: 354=4, 356=8, 359=16
13 Carbapenem Monotherapy in 50 Patients with Serious CPE Infections (Results compiled from 15 studies) MIC (μg/ml) No. of patients No. of successes No. of failures % failure > Tzouvelekis et al CMR 2012; 25:
14 205 patients with CP Kp bacteremia Treatment with a combination: Independent predictor of survival!! P=0.003 Mortality % No active drug 33.3 Monotherapy 44.4 Combination 27.2 without a carbapenem 30.6 with a carbapenem and MIC 8 mg/l 19.3 and MIC>8 mg/l 35.5 P 0.018
15 Mortality associated with different antimicrobial drug regimen categories in patients with different presenting features or in patients with different KPC-Kp isolate characteristics Tumbarello M et al JAC 2015; 70: 2133
16 Effect of combination therapy containing a high-dose carbapenem on mortality in patients with CR-Kp BSIs Post hoc analysis of the Italian cohort of 595 pts with CR- Kp BSIs who received combination therapy Meropenem dose: 2g q 8h, 3h infusion Cox regression analysis adjusted for the propensity score to account for population imbalances between patients receiving combination therapy with or without meropenem Outcome: 14 day mortality Gianella M IJAA 2018; 51:
17 Cox Regression Analysis Adjusted for the Propensity Score Variable HR (95% CI) P Charlson CI 1.65 ( ) <0.001 Corticosteroids 1.93 ( ) Surgical ward 0.44 ( ) Septic Shock 4.7 ( ) <0.001 Colistin resistance 1.65 ( ) Carbapenem combination 0.64 ( ) 0.03 Gianella M IJAA 2018; 51:
18 Cox Regression Analysis of Survival Stratified for Carbapenem MIC ahr for carbapenem combination 0.63, 95%CI , P=0.03 Giannella M et al IJAA 2018; 51:
19 Nomograms based on CLCr estimates for the calculation of the meropenem daily dosage administered by continuous infusion which is necessary for the achievement of a target Css of 8 mg/liter (circles), 12 mg/liter (triangles), and 16 mg/liter (squares) in critically ill patients. Pea F et al. 2012;56:
20 Optimal PK/PD exposure with TDM Maximum permissible Css: mg/l Target: Css/MIC: 1-4mg/L Continuous infusion of MEM 1.7g-13.2g/day Clinical Outcome MIC 16mg/L; Cure 14/15 (93%) MIC 32-64mg/L; Cure 8/12 (67%) MIC >64mh/L; Cure 0/3 (0%)
21 Univariate regression analysis of variables associated with clinical cure from KPC-Kp related infections Variable OR (95%CI) P-value Charlson CI ( ) 0.05 Site of Infection, BSI ( ) 0.09 Meropenem MIC ( ) 0.07 Meropenem Css/MIC ( ) 0.01 Meropenem Css/MIC ( ) 0.03 No. of co-administered antimicrobials 1 active drug 2 active drugs Pea F et al IJAA 2017; 49: ( ) ( )
22 Probability of target attainment (PTA) of 100% T>1 MIC with some permissible high-dose continuous-infusion meropenem regimens in relation to different classes of renal function. Piergiorgio Cojutti et al. Antimicrob. Agents Chemother. 2017;61:e
23 Dosing algorithm for choosing the most advisable high-dose continuous-infusion meropenem regimen in relation to different classes of renal function for the empirical treatment of infection suspected to be caused by Klebsiella pneumoniae carbapenemaseproducing Klebsiella pneumoniae (KPC-Kp). Piergiorgio Cojutti et al. Antimicrob. Agents Chemother. 2017;61:e
24 Summary (Carbapenems) High-dose continuous-infusion of meropenem associated with TDM to drive the PK/PD profile to acceptable exposures (100% T>1-4XMIC) can be used For CPE infections with MEM MIC up to 64 mg/l Provided that his class of agents is administered in combination with another active compound
25 PK/PD Targets for Aminoglycosides Cmax/MIC 8 AUC/MIC 70
26
27 Expected Gentamicin Peak/MIC and AUC/MIC Values for Organisms with High MICs (Craig W ESCMID Lecture Library) PK/PD Index MIC 5mg/kg 7mg/kg 10mg/kg Peak/MIC AUC/MIC Peak/MIC AUC/MIC Peak/MIC AUC/MIC 1 1 EUCAST 2 2 CLSI
28 Distribution of Peak Concentrations of Amikacin after Loading dose 25mg/kg in 74 ICU patients with Sepsis Taccone et al. Critical Care 2010, 14:R53 MIC=8mg/L Cmax/MIC 8 Target achieved In 70% of pts
29 P= pts with KPC infections; 29 received gentamicin as monotherapy or combination Genta MIC 2mg/L=13 Genta MIC >2-4 mg/l=16 Genta dose 4-5 mg/kg/24h Targets: Cmax=15-20 mg/l, Cmin 1mg/L
30 Factors associated with clinical success following aminoglycoside therapy for CR-Kp bacteremia. Overall clinical success rate was 54% All cause 30-day mortality was 30% Ryan K. Shields AAC 2016; 60: 3187
31 15 adult ICU patients with MDR-GN infections High-dose AMK (median, 29mg/kg, GM (11 mg/kg) Infecting organism MIC S by EUCAST CVVHDF high flow at >45ml/kg/h PK/PD target: Cmax/MIC 8-12, AMK toxicity; Cmin 5 mg/l, GN toxicity 2 mg/l
32
33 Multivariate Analysis of Factors Associated with in Hospital Mortality in 258 Patients with MDR-GN Infections Treated with Colistin Variable aor (95%CI) P Higher colistin dose 1.22 ( ) APACHE II 0.89 ( ) <0.001 Hematologic diseases 0.23 ( ) Cure of infection 9 ( ) <0.001 Creatinine rise 0.21 ( ) < Falagas et al IJAA 2010; 35:
34 2016; 63(12): consecutive patients; 144 were treated with HD colistin (9 MIU) and 385 with lower-dose (4MIU) In the propensity-matched cohort no difference in mortality was observed between the groups treated with HD or LD Nephrotoxocity was significantly more common with HD
35 PK/PD Therapeutic Target for Optimization of Colistin Efficacy AUC 0-24h 50 mg.h/l which is equivalent to a target average steady-state plasma concentration Css,avg of 2 mg/l This target should be considered as a maximum tolerable exposure, as concentrations higher than this have been shown to increase the incidence and severity of AKI fauc/mic is the PK/PD index that correlates best with antibacterial activity Nation et al CID 2017; 64: 565
36 Patients with Increased CrCL Creatinine Clearance (ml/min/1.73m 2 ) Garonzik et al, AAC 2011 & ECCMID 2013 Karaiskos et al, AAC 2015; 59: 7240 In patients with high CrCL there is decreased ability to reliably attain plasma colistin Css,avg 2mg/L Only 11/39 patients with CrCl > 80 attained Css,avg 2mg/L (1) Only 4/12 patients with CrCl > 80 attained Css,avg 2mg/L (2) Proportion of pts who attained a plasma colistin - Css,avg 2 mg/l Garonzik et al Karaiskos et al /7 2/ /16 0/ /10 1/2 >140 1/6 1/3
37 Daily Doses of CMS for a Desired Target Colistin Css,avg of 2 mg/l Creatinine clearance, ml/min CBA, mg/d Dose of Colistimethate Million IU/d to < to < to < to < to < to < to < to < to < Nation et al CID 2017; 64: 565
38 Continuous Renal Replacement Therapy-Related Strategies to Avoid Colistin Toxicity: A Clinically Orientated Review Patrick M. Honoré a Rita Jacobs a Olivier Joannes-Boyau d Stijn Lochy a Willem Boer c Elisabeth De Waele a Viola Van Gorp a Jouke De Regt a Vincent Collin b Herbert D. Spapen a a Department of Intensive Care Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, and b Clinique de L Europe St. Michel, Brussels, and c Department of Anesthesiology and Critical Care Medicine, Ziekenhuis Loading Oost-Limburg, Genk dose, Belgium; of d Haut colistin: Leveque University 9 Hospital MIU of Bordeaux, University of Bordeaux 2, Pessac, France Maintenance dose 4.5 MIU q 8h CVVH at 35 ml/kg/h Key Words Acute kidney injury Colistin Colistin dosing Continuous renal replacement therapy Dialysis Nephrotoxicity Renal replacement therapy Highly adsorptive filters Abstract Polymyxins Blood are Purif old antimicrobials 2014;37: which were abandoned for almost 30 years because of significant renal and neurological toxicity. However, the alarming rise in multiresistant perience, we postulate that patients undergoing CRR receive substantially higher doses of colistin (i.e. a high ing dose, followed by a maintenance dose of up to 4 lion IU t.i.d.). Treatment can be continued for a prol time period without increasing toxicity. CRRT count colistin accumulation because the drug is continuou tered and also significantly adsorbed in the bulk of the sis membrane. Implementing such a CRRT rescue th does require the strict use of highly adsorptive dialysis branes in association with citrate anticoagulation to in
39 MIC distributions of 164 CP-KP strains And KP from EUCAST MIC distribution doi.org/ / PTA (fauc/mic >0.9) 10,000 simulated pts given tigecycline at different dosages
40 Cumulative Fraction Response (CFR) for Achieving PK/PD with Tigecycline against CP-KP and KP from the EUCAST MIC Distribution PK/PD Index fauc/mic>0.9 Antibiotic regimen Tigecycline 50mg q 12h Tigecycline 75mg q 12h Tigecycline 100mg q 12h CP-KP CFR (%) EUCAST doi.org/ /
41 Logistic regression analysis of factors associated with clinical cure in 63 patients with ventilator-associated pneumonia
42 30 patients with IAIs 12 received high-dose tigecycline in combination with colistin 18 received standard-dose of tigecycline in combination with colistin
43 23 received TIG 100 mg q 12h - Mortality: 52% 17 received TIG 50 mg q 12h - Mortality: 76.5%
44
45 Conclusions Real-time TDM may improve drug exposure and result in better clinical outcome. High-flow CRRT may prove a valuable tool to achieve acceptable PK/Pd profile for nephrotoxic agents (AG and colistin) in critically ill patients infected with CRE organisms while avoiding drug accumulation and toxicity.
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationESCMID Online Lecture Library. by author
Novel PK/PD data on the optimisation of colistin and the carbapenems Diamantis Plachouras Athens, Greece Hot Topics on Infections in the Critically Ill Patient, ESCMID Postgraduate Education Course, 31
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationDiane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center
Diane M. Gomes, Pharm.D. Outcomes in Antimicrobial Stewardship Post-Doctoral Pharmacy Fellow Providence Veterans Affairs Medical Center The information disseminated in this lecture is given in my personal
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationIs the package insert correct? PK considerations
Is the package insert correct? PK considerations Jason A Roberts B Pharm (Hons), PhD, FSHP Professor of Medicine and Pharmacy The University of Queensland, Australia Royal Brisbane and Women s Hospital,
More informationDisclosures. Efficacy of the drug. Optimizing Dosing Based on PKPD- An overview. Dose Finding - The Past
Disclosures Optimizing Dosing Based on PKPD- An overview Johan W. Mouton MD PhD FIDSA FAAM Professor pharmacokinetics and pharmacodynamics Research grants advisory boards speaker This Patient Needs Antibiotics.
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More information%T MIC MIC. Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration time-killing-curve 1990.
THE JAPANESE JOURNAL OF ANTIBIOTICS 58 2 159( 55 ) ( 2 15 ) %T MIC MIC 2002 30%T MIC 50%T MIC 1000 mg 3 3 /day Pharmacokinetics PK: Cmax AUC T1/2 Pharmacodynamics PD: MIC: minimum inhibitory concentration
More informationBasic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics
Basic Concepts of PK/PD -pharmacodynamic indices- Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodymamics This patient needs antibiotics. But which ones? Intensive care patient Ceftazidime,
More informationSCMID Online Lecture Library. by author. Optimizing antimicrobial therapy in the elderly. Dose Finding - The Past
Optimizing antimicrobial therapy in the elderly Johan W. Mouton MD PhD FIDSA Professor pharmacokinetics and pharmacodynamics Dosing should be such that the level of antmicrobial activity is associated
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More information27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria, April 22-25, 2017
Is Associated With Improved Survival and Safety Compared With in the Treatment of Serious Infections Due to Carbapenem-resistant Enterobacteriaceae: Results of the CARE Study Lynn E. Connolly 1, Adrian
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationAchieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first dose: Can we do it with standard dosing?
Oral session: PK/PD-based optimized broad-spectrum beta-lactam therapy (Sunday 10 April, 11:30) Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of β-lactams in critically ill patients at first
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationTreatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
REVIEW ARTICLE Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections Haley J. Morrill, 1,2 Jason M. Pogue, 3 Keith S. Kaye, 4 and Kerry L. LaPlante 1,2,5 1 Veterans Affairs Medical Center,
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationVoriconazole Rationale for the EUCAST clinical breakpoints, version March 2010
Voriconazole Rationale for the EUCAST clinical breakpoints, version 2.0 20 March 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationOptimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology
ATHENA 2017 International Conference November 28 30, 2017 Optimizing antifungal dosing regimens Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology Clinical Microbiology Laboratory, «Attikon»
More informationCLINICAL USE OF GLYCOPEPTIDES. Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel
CLINICAL USE OF GLYCOPEPTIDES Herbert Spapen Intensive Care Department University Hospital Vrije Universiteit Brussel Glycopeptides Natural Vancomycin introduced in 1958 Teicoplanin introduced in Europe
More informationANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO
ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland NO CONFLICT OF INTERESTS Important concept
More informationProfessor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence
Professor of Chemotherapy Department of Preclinical and Clinical Pharmacology University of Florence Researching field Pharmacokinetics, Pharmacodynamics of antimicrobial, antifungal and antitumoral drugs
More informationDoripenem: pharmacokinetics and pharmacodynamics. Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD
16/04/2009 1 Doripenem: pharmacokinetics and pharmacodynamics Paul M. Tulkens, MD, PhD Françoise Van Bambeke, PharmD, PhD Unité de Pharmacologie cellulaire et moléculaire Louvain Drug Research Institute
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationPharmacodynamic indices in targeting therapy of critical infections
Pharmacodynamic indices in targeting therapy of critical infections P.M. Tulkens Cellular and Molecular Pharmacology, Catholic University of Louvain, Brussels, Belgium & International Society of Anti-infective
More informationTDM of Aminoglycoside Antibiotics
TDM Lecture 3 5 th Stage TDM of Aminoglycoside Antibiotics The aminoglycoside antibiotics are widely used for the treatment of gram-negative infections, often in combination with a β-lactam antibiotic
More informationAntibiotic Treatment of GNR MDR Infections. Stan Deresinski
Antibiotic Treatment of GNR MDR Infections Stan Deresinski Kucers: The Use of Antibiotics 1st Edition 1972 392 pages Kucers: The Use of Antibiotics 7 th Edition 2017 5338 pages Carbapenem Susceptibility
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationShould we be performing TDM in seriously ill patients with Gram negative infections?
Should we be performing TDM in seriously ill patients with Gram negative infections? Jason A Roberts B Pharm (Hons), PhD, FSHP Royal Brisbane and Women s Hospital, Australia. The University of Queensland,
More informationwithout the permission of the author Not to be copied and distributed to others
Emperor s Castle interior-prato What is the Role of Inhaled Polymyxins for Treatment of Respiratory Tract Infections? Helen Giamarellou CONCLUSIONS: Patients with Pseudomonas and Acinetobacter VAP may
More informationPHA Spring First Exam. 8 Aminoglycosides (5 points)
PHA 5128 Spring 2012 First Exam 1 Aminoglycosides (5 points) 2 Aminoglycosides (10 points) 3 Basic Principles (5 points) 4 Basic Principles (5 points) 5 Bioavailability (5 points) 6 Vancomycin (5 points)
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationPharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically ill patients
Veiga and Paiva Critical Care (2018) 22:233 https://doi.org/10.1186/s13054-018-2155-1 REVIEW Pharmacokinetics pharmacodynamics issues relevant for the clinical use of betalactam antibiotics in critically
More informationUse of Colistin. Dr. Maya Hites Dept. of Infectious Diseases CUB-Erasme, Université Libre de Bruxelles NVMM/VIZ/BVIKM/SBIMC Fall Meeting 17/11/2017
Use of Colistin Dr. Maya Hites Dept. of Infectious Diseases CUB-Erasme, Université Libre de Bruxelles NVMM/VIZ/BVIKM/SBIMC Fall Meeting 17/11/2017 Disclosure (potential) conflict of interest For this meeting
More informationPlazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study
Plazomicin Versus Meropenem for the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: Results of the EPIC Study Daniel J. Cloutier 1, Loren G. Miller 2, Allison S. Komirenko 1,
More informationAminoglycosides John A. Bosso, Pharm.D.
AMINOGLYCOSIDES Therapeutics/PHRMP-73 Aminoglycoside Mechanism of Action Aminoglycosides bind to 30s ribosomal subunit resulting in mistranslation of mrna thus disrupting protein synthesis. They are rapidly
More informationAugmented Renal Clearance: Let s Get the Discussion Flowing
Augmented Renal Clearance: Let s Get the Discussion Flowing Terry Makhoul, PharmD PGY-2 Emergency Medicine Pharmacy Resident University of Rochester Medical Center Strong Memorial Hospital Disclosures
More informationPharmacodynamics: the methods
Pharmacodynamics: the methods In vitro models Animal models Clinical studies Population studies With the support of Wallonie-Bruxelles-International 3B-1 Pharmacodynamics: the methods "un peu de tout "
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationPK/PD degli antibiotici utilizzati nella sepsi
PK/PD degli antibiotici utilizzati nella sepsi Dario Cattaneo, U.O. Farmacologia Clinica ASST Fatebenefratelli Sacco, Milano Bergamo, città alta Variability of antibiotic concentrations in critically ill
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationContinuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients
Continuous vs Intermittent Dosing of Antibiotics in Critically-Ill Patients Jan O Friedrich, MD DPhil Associate Professor of Medicine, University of Toronto Medical Director, MSICU St. Michael s Hospital,
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More information2/6/14. What s Hot in ID Objectives
What s Hot in ID 2014 James S. Lewis II, Pharm.D., FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Portland, OR Objectives Describe highlights of the Interscience Conference
More informationPHARMACOKINETICS OF COLISTIN IN
PHARMACOKINETICS OF COLISTIN IN CRITICALLY ILL PATIENTS WITH MULTIDRUG-RESISTANT GRAM- NEGATIVE BACILLI INFECTION JOURNAL CLUB PRESENTATION Amal M. Al-Anizi, PharmD Candidate KSU, Infectious disease rotation
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN
ZIN EN ONZIN VAN ANTIBIOTICASPIEGELS BIJ NEONATEN Anne Smits Fellow neonatologie UZ Leuven Use of antibiotics in neonates 50 European hospitals 23 non-european hospitals Countries n = 14 n = 9 Pediatric
More informationSuperhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia
Superhero or Superzero? Vancomycin vs. Linezolid for MRSA Pneumonia Brandon Dionne, PharmD, BCPS, AAHIVP Assistant Clinical Professor Northeastern University Seth Housman, PharmD, MPA Clinical Assistant
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationComment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines. Nouvelles molécules
Comment l EUCAST fixe les concentrations critiques (Breakpoints), Associations inhibiteurs de ß-lactamases et ß-lactamines Nouvelles molécules L. Dubreuil Maître de conférences en Pharmacologie Professeur
More informationEXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? Prof Patrick Honoré,MD, PhD, Intensivist-Nephrologist
EXTRACORPOREAL TECHNIQUES IN MODS: An Update :Techniques For Organ Support Where Are We In 2013? 1.-CRRT : A «Lego» Module? 4.-Antibiotic Adaptation During Low Dose CRRT? 2.- CRRT + ECMO: What to do? 5.-
More informationMedication Dosing in CRRT
Medication Dosing in CRRT Linda Awdishu, PharmD, MAS Associate Clinical Professor of Pharmacy and Medicine Learning Objectives 1. List the pharmacokinetic changes associated with AKI. 2. Determine the
More informationESCMID Online Lecture Library. by author
www.eucast.org EXPERT RULES IN ANTIMICROBIAL SUSCEPTIBILITY TESTING Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA Departamento de Microbiología II Universidad
More informationNew insights in antibiotic and antifungal therapy in the compromised host
New insights in antibiotic and antifungal therapy in the compromised host Claudio Viscoli University of Genova Ospedale Policlinico San Martino, Genova Potential conflicts of interest (last 5 years) Received
More informationAMINOGLYCOSIDES TDM D O N E B Y
AMINOGLYCOSIDES TDM DONE BY: SARA ALARFAJ 2014 OUTLINE Introduction about Aminoglycosides. Spectrum/uses. TDM Aminoglycosides TDM Pharmacodynamics Pharmacokinetics. Dosing in AG. Sampeling time and Monitoring.
More informationReceived 13 December 2010/Returned for modification 13 March 2011/Accepted 28 April 2011
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, July 2011, p. 3284 3294 Vol. 55, No. 7 0066-4804/11/$12.00 doi:10.1128/aac.01733-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Population
More informationThe antibiotic dose and the obese ICU patient
The antibiotic dose and the obese ICU patient Philippe Montravers, M.D., Ph.D. Anaesthesia and Surgical ICU CHU Bichat Claude Bernard Assistance Publique-Hôpitaux de Paris INSERM UMR 1152 University Paris
More informationBack to the Future: Using Aminoglycosides Again and How to Dose Them Optimally
INVITED ARTICLE ANTIMICROBIAL RESISTANCE George M. Eliopoulos, Section Editor Back to the Future: Using Aminoglycosides Again and How to Dose Them Optimally George L. Drusano, Paul G. Ambrose, Sujata M.
More informationDepartment of Clinical Pharmacy, University of Michigan College of Pharmacy, Pharmacy Faculty, Siam University, Bangkok, Thailand
1 2 Article Type: Guest Ed Mistakes We Make in Dialysis 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 We underdose antibiotics in patients on CRRT Alexander R. Shaw Weerachai Chaijamorn Bruce A. Mueller 1 Ann
More informationby author ESCMID Online Lecture Library
The Karyatides at the Erechtheion Temple Devoted to the Women in the Audience At the top of the Museum the Karyatides, watching you through the years to come FOSFOMYCIN IN THE TREATMENT OF INFECTIONS
More informationDrug Management in CRRT
Drug Management in CRRT Jeffrey Lipman, FCICM, MD Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Bruce A. Mueller, PharmD, FCCP, FASN Clinical, Social & Administrative
More informationDosing Guidance for Intravenous Colistin in Critically Ill Patients
Clinical Infectious Diseases MAJOR ARTICLE Dosing Guidance for Intravenous Colistin in Critically Ill Patients Roger L. Nation, 1 Samira M. Garonzik, 3 Visanu Thamlikitkul, 5 Evangelos J. Giamarellos-Bourboulis,
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationCarbapenemase Producing Enterobacteriaceae: Screening
Carbapenemase Producing Enterobacteriaceae: Screening Dr David Harvey Consultant Microbiology and Infection Prevention and Control Nov 2015 Aims Is CPE a problem? Does screening have the potential to help?
More informationR EVIEWS O F T HERAPEUTICS
R EVIEWS O F T HERAPEUTICS Colistin: Understanding and Applying Recent Pharmacokinetic Advances Jessica K. Ortwine, 1 Keith S. Kaye, 2,3 Jian Li, 4 and Jason M. Pogue 3,5 * 1 Department of Pharmacy Services,
More informationGUIDANCE ON TREATMENT OF CARBAPENAMASE PRODUCING ENTEROBACTERIACEAE
GUIDANCE ON TREATMENT OF CARBAPENAMASE PRODUCING ENTEROBACTERIACEAE June 2016 1 UKCPA Pharmacy Infection Network Carbapenamase producing Enterobacteriaceae (CPE) treatment guidance Acknowledgements This
More informationSBUH Aminoglycoside Dosing Protocol
Adult Aminoglycoside Dosing for Gram negative infections prior to available serum levels (Excludes patients with cystic fibrosis, OB GYN patients and surgical prophylaxis) Cr Cl 40 ml/min 5 7 mg/kg INT
More informationAUGMENTED RENAL CLEARANCE and its clinical implications. Professor Jeffrey Lipman
AUGMENTED RENAL CLEARANCE and its clinical implications Professor Jeffrey Lipman Department of Intensive Care Medicine Royal Brisbane Hospital University of Queensland Introduction Recommended dosages
More informationStanford Health Care Last Review Date: 8/2016 Pharmacy Department Policies and Procedures
Medication Administration: Extended-Infusion Piperacillin/Tazobactam (Zosyn ) Protocol Related Documents: Patient Care Manual Guide: Medication Administration IV Infusion Guidelines I. PURPOSE Dose optimization
More informationOptimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria
Infect Dis Ther (2015) 4:391 415 DOI 10.1007/s40121-015-0093-7 REVIEW Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria Phillip J. Bergen Zackery P. Bulman Cornelia B. Landersdorfer
More informationMechanisms of Resistance to Ceftazidime-Avibactam. Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics.
Mechanisms of Resistance to Ceftazidime-Avibactam Romney M. Humphries, PhD D(ABMM) Chief Scientific Officer Accelerate Diagnostics UCLA, January 2015 62 year old woman with advanced pancreatic cancer Vomiting
More informationBSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin
BSWH Pharmacist Continuing Education 2015 PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin Objectives Define basic pharmacodynamic and pharmacokinetic principles Describe
More informationAdult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016
Adult Inpatient Antibiogram Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates January to December 2016 Department of Pathology Camille Hamula, PhD Director, Clinical Microbiology
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationPlazomicin for complicated urinary tract infection
October 2016 Horizon Scanning Research & Intelligence Centre Plazomicin for complicated urinary tract infection NIHR HSRIC ID: 9787 Lay summary Serious infections caused by Gram-negative bacteria are becoming
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationprophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures
1 Glycopeptides appropriate uses serious infections due to beta-lactam- resistant gram-positive microorganisms infections due to gram-positive microorganisms in patients with serious allergy to beta-lactam
More informationCurrent concepts in combination antibiotic therapy for critically ill patients
Short Communication Current concepts in combination antibiotic therapy for critically ill patients Armin Ahmed, Afzal Azim, Mohan Gurjar, Arvind Kumar Baronia Abstract Widespread emergence of multidrug
More informationPaul M. Tulkens Françoise Van Bambeke. Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute
New antimicrobials Paul M. Tulkens Françoise Van Bambeke Unité de pharmacologie cellulaire et moléculaire & Louvain Drug Research Institute Université catholique de Louvain,, Brussels, Belgium Slides are
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationConsequences for the clinicians
30th Symposium : What will change in your daily practice with the new Elewijt, 26-05-2008 EUCAST breakpoints for antibiotic susceptibility testing Consequences for the clinicians Y.Van Laethem,MD CHU St
More informationClinical Infectious Diseases Advance Access published July 2, 2012
Clinical Infectious Diseases Advance Access published July 2, 2012 1 Predictors of Mortality in Bloodstream Infections Caused by KPC-Producing Klebsiella pneumoniae: Importance of Combination Therapy Mario
More informationDrug-resistant Infections
Treatment Options for Infections Caused by Carbapenem-resistant Gram-negative Bacteria Chris Kosmidis, 1 Garyphalia Poulakou, 2 Antonios Markogiannakis 3 and George L Daikos 4 1. Research Associate, First
More informationUse ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:
Amikacin is a partially restricted (amber) antibiotic for the treatment of infections due to gentamicin resistant Gram negative bacilli or as advised by microbiology. As with other aminoglycosides, therapeutic
More informationEMA Workshop Estimating the Probability of Target Attainment
EMA Workshop Estimating the Probability of Target Attainment G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation University of Florida Attainment We all tend to think problems
More informationPharmacodynamics of sulfamethoxazole in in vitro and in vivo models of tuberculosis
Pharmacodynamics of sulfamethoxazole in in vitro and in vivo models of tuberculosis Jin Lee 1, Sandeep Tyagi 1, Eric L. Nuermberger 1 1 Johns Hopkins University School of Medicine, Baltimore, MD, Trimethoprim-sulfamethoxazole
More informationThe Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa
The Challenge of MDR and XDR infections Friday 14th September, Barcelona Multi-drug and Extremely drug-resistant Pseudomonas aeruginosa Juan P. Horcajada Service of Infectious Diseases Hospital del Mar,
More informationPolymyxin B and Colistin Debate: One of the Same Kind or Mutt and Jeff?
Polymyxin B and Colistin Debate: One of the Same Kind or Mutt and Jeff? Bruce M. Jones, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases St. Joseph's/Candler Health System, Inc. Clinical Adjunct
More informationTowards clinical Applications of PK-PD in specific situations
Towards clinical Applications of PK-PD in specific situations P.M. Tulkens Cellular and Molecular Pharmacology & Center for Clinical Pharmacy, Catholic University of Louvain, Brussels, Belgium with many
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More information